COR1.1

Shares of Carbylan Therapeutics Inc (NASDAQ: CBYL), a nano-cap clinical-stage specialty pharmaceutical company, plunged nearly 50 percent after the company announced top-line results from a Phase 3 trial, COR1.1. COR1.1 was a 560 patient, international, multi-center and randomized double-blind...